Conflict of Interest
The author declares the following competing financial interest(s): R. Khanna is the co-founder of Regulonix LLC, a company developing non-opioids drugs for chronic pain. In addition, R. Khanna has patents US10287334 (Non-narcotic CRMP2 peptides targeting sodium channels for chronic pain) and US10441586 (SUMOylation inhibitors and uses thereof) issued to Regulonix LLC. R. Khanna and A. Moutal are co-founders of ElutheriaTx Inc., a company developing gene therapy approaches for chronic pain.